Article info
PDFClinical science
Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma
- Correspondence to Professor Steffen Heegaard, Department of Pathology, Eye Section, Rigshospitalet, Copenhagen 2100, Denmark; sthe{at}sund.ku.dk
Citation
Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma
Publication history
- Received May 2, 2021
- Accepted October 10, 2021
- First published October 27, 2021.
Online issue publication
March 22, 2023
Article Versions
- Previous version (22 March 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.